71172-70-8

Basic information

• Product Name: ethyl 4-propylpiperazine-1-carboxylate
• Synonyms: ethyl 4-propylpiperazine-1-carboxylate;4-Propyl-1-piperazinecarboxylic acid ethyl ester
• CAS NO: 71172-70-8
• Molecular Formula: C₁₀H₂₀N₂O₂
• Molecular Weight: 200.278
• EINECS: 275-239-9
• Mol File: 71172-70-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 267.9°C at 760 mmHg
• Flash Point: 115.8°C
• Appearance: /
• Density: 1.017g/cm³
• Vapor Pressure: 0.00794mmHg at 25°C
• Refractive Index: 1.472
• CAS DataBase Reference: ethyl 4-propylpiperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-propylpiperazine-1-carboxylate(71172-70-8)
• EPA Substance Registry System: ethyl 4-propylpiperazine-1-carboxylate(71172-70-8)

Safety Data

• Hazardous Substances Data: 71172-70-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H20N2O2/c1-3-5-11-6-8-12(9-7-11)10(13)14-4-2/h3-9H2,1-2H3

Upstream product

• 120-43-4 4-ethoxycarbonylpiperazine 

Downstream Products

• 64262-23-3 1-n-propylpiperazine dihydrobromide 

Relevant articles and documents

Novel water-soluble sedative-hypnotic agents: Isoindolin-1-one derivatives

We developed new intravenous sedative-hypnotic compounds with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. We synthesized approximately 170 derivatives and evaluated their hypnotic effects by intravenous administration of the compounds to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs, 3(-), 5(-), 27(-), and 47(-) [JM-1232(-)], showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compounds when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, respectively, and the lethal doses (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, respectively. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, respectively. Among these compound, 47(-) [JM-1232(-)] is being considered as the most potential candidate for clinical trials in humans.

2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use

The present invention provides substituted dibenzoxazepine and dibenzthiazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, and for prostaglandin-E2 mediated diseases, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal, and a method for treating prostaglandin-E2 mediated diseases in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.